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1 7a-methyl-B-nortestosterone depresses semi-
nal vesicle and ventral prostate Weights in
intact and androgen-treated castrated rats and
mice. The androgenic stimulation of the chick-
comb growth is also depressed by this agent
(1), and it has been shown to inhibit andro-
gen-stimulated sebum prodnction in the rat
(2). This latter finding is of interest because
of androgen-enhanced scbum production in
man (3—5) and its possible correlation with
acne (6,7).
Estrogen also decreases sebum production in
the androgen-stimulated rat, probably by in-
terfering with intracellular synthesis. This
mechanism is different from that of 17a-
methyl-B-uortestosterone. Estrogen does not
significantly affect the incidence of mitoses,
whereas 17a-methyl-B-nortestosterone reduces
the incidence in proportion to its effect on
sebnm production (2).
This report concerns the effect of a 6-cyclo-
propyl substituent on the antiandrogenic and
sebum-inhibiting properties of 17cr-methyl-B-
nortestostcrone.
MATERIALS AND METHODS
Antiandrogenic activity was assessed in intact(135 gm) male rats or in testosterone-treated
(2.5 mg/kg/day subcutaneously immature (55
gm) castrated rats. 6a ,6j9-etbylene-17a-methyl-B-
nortestosteroae (SK&F 22340) was administered
orally once a day for seven days. The animals
wore sacrificed by decapitation on the eighth day
and the seminal vesicles, ventral prostate, and
levator ani muscles were removed and weighed.
Antiandrogenie activity in the chick was deter-
mined as previously described (1). In these studies,
l7cr-methyl-B-nortestosterone (SK&F 7600) was
administered as a reference standard for eompara-
two purposes.
Androgenic activity was evaluated in immature
(85 gm) male rats castrated three days prior to
commencing treatment. SK&F 22340 was admin-
istered orally in sesame oil in doses ranging from
1.5 to 06 mg/kg/day for seven days. The animals
were sacrificed on the eighth day and the seminal
vesieles, ventral prostate, and levator ani muscles
were removed and weighed.
Uterotrophic activity was determined in im-
mature ovariectomized rats. SK&F 22340 was
administered orally in sesame oil in doses ranging
from 12.5 to 100 mg/kg/day for three days. Ethynyl
estradiol served as an oral reference standard;
it was administered in doses ranging from 125 to
10.0 meg/kg/day. The animals were sacrificed on
the fourth day and the uteri were removed and
weighed after the luminal fluid was expressed.
The ability to induce vaginal cornification was
evaluated in mature ovarieotomized rats in which
a cornified vaginal epithelium had been elicited
ten days previously by the administration of
estradiol. SK&F 22340 was administered for two
days at a dose of 50 mg/kg b.i.d. Vaginal smears
were taken 48, 55, and 72 hours after the first in-
jection, and the presence of cornified epithelial
cells in the absence of leuoocytes was considered
positive evidence of estrus:
The ability to inhibit ovarian hypertrophy in
unilaterally ovarieetomized rats was utilized as an
index of antigonadotrophie activity. Female rats
(190 gm) were unilaterally ovariectomized the day
treatment commenced. SK&F 22340 was admin-
istered orally in sesame oil at a dose of 100 mg/
kg/day for ten days. The rats were sacrificed on
the eleventh day and the remaining ovary was
removed and weighed. Testosterone was employed
as a reference standard of antigonadotrophic
activity. To determine its ability to inhibit the
antigonadotrophic effect of testosterone, SK&F
22340 was administered orally to rats which re-
ceived a concurrent subcutaneous dose of testos-
terone of 1 mg/kg/day for ten days.
Effects on sebaceous gland sebum production
were determined in female rats obtained from
eleven litters, each of which consisted of six rats.
The rats were spayed at 4—6 weeks of age and
were 15—19 weeks old at the start of treatment.
All rats were subcutaneously implanted with
testosterone (about 8 mg, with a daily uptake of
about 0.2 mg). In addition, one rat in each litter
was given one of the following treatments: 1)
control, with no additional treatment; 2) subcu-
taneous estradiol (implant, 1:9 in cholesterol,
about 5 mg, with a daily uptake of about 2-4
pg estradiol); 3) one mg subcutaneously/day of
l7ce-methyl-B-nortestosterone (in 0.2 ml of 1%
oarboxymotliyl-eellulose in 0.9% NaCU; 4) 10 mg
,suhcu taneously/day of llcr-methyl-B-nortestos-
terone; 5) one mg subcutaneously/day of SK&F
22340; and 6) 10 mg subcutaneously/day of
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SK&F 22340. Rat cake (Oxoid diet 86) and water
were available ad libitum.
Sebum production was assessed by measuring
the increase in the amount of ether-extractable
hair fat over an eigbt-day period (8). Fifteen
days after the start of treatment, each rat was
sbampooed with sodium lauryl sulphate and warm
water, and dried with a hair dryer. A second
washing was carried out the following day and,
immediately after drying, about one gm of hair
was clipped from the left flank of the rat and
weighed. Then the hair was successively extracted
with five 50 ml portions of diethyl ether. The ex-
tracts from each sample were combined in tared
aluminum foil cups, evaporated to dryness on a
hot plate, and weighed. The amount of hair fat was
expressed as mg/gm hair. Eight days later, a sample
of hair was clipped from the right flank of each
rat and treated in the same fashion. Thus, the
increase in hair fat in mg/gm hair/day could be
calculated for the period between 16 and 24 days
after the start of treatment.
On the 24th day after the start of treatment,
each rat was injected intraperitoneally at 10.00
hr with 0.1 mg eolehieine in water/100 gm body
weight. Colehieine arrests cells entering mitosis
in the metaphase, and thus it can be used to
determine the incidence of mitoses in the se-
baceous glands of the rat (9). The rats were
killed at 15.00 hr. The testosterone-treated con-
trol rats weighed from 192 to 263 gm. The skins
were removed, pinned to cork boards, and fixed.
Samples taken from near the midline in the
anterior region of the back were sectioned at 7 p
and stained in Ehrlich's hematoxylin and ethano-
lie eosin.
In order that comparable material could be
examined for each rat without bias, the number of
arrested metaphases in 50 consecutive sections of
sebaceous glands was counted. The length of skin
section occupied by the count was also measured,
and the number of mitoses per unit length of
section was then calculated. The latter figure is
a proportional measure of the mean rate of pro-
duction of cells per sebaceous gland, because the
number of mitoses on a cut face is proportional to
the total number in any block of skin, and it is
known that the number of sebaceous glands per
unit area does not change as a result of the treat-
ments under investigation (10—12).
RESULTS
At oral doses of 12.5, 25, 50, and 100 mg/kg/
day, SK&F 22340 significantly reduced the
weights of the seminal vesicles and the ventral
prostates in the intact rat (Table I). The
weights of the lcvator ani muscles were not
significantly decreased until doses of 50 and
100 mg/kg were administered. The decrease in
weight of the seminal vesieles was the only
endpoint which exhibited a dose-response re-
lationship; when the method of least squares
was employed, SK&F 22340 possessed 3.1 times
the antiandrogenic activity of SK&F 7690.
In the immature castrated rat receiving
TABLE I
Antiandrogenic activity of SK&P 22840 & 17a-methyl-B-nortestosterone in intact rats
Treatmenta
Relative organ weights (mg/Ito Gm) (Mean S.F.)
Seminal vesicles Ventral prostate Levater ani
Intact controls 102.9 14.5 77.0 5.1 38.5 3.5
Castrate controls 23.4 2.2 14.9 1.8 23.5 1.1
Intaets + 17a-methyl-B-nortes-
tosterone
12.5 mg/kg/day p.o. 78.8 6.1 61.9 5.7 31.6 2.5
25 mg/kg/day p.o. 71.6 3.5 56.9 33** 31.9 1.7
50 mg/kg/dayp.o. 60.5 93* 58.0 6.2* 29.5 1.9
100 mg/kg/dayp.o. 41.7 6.4** 50.1 39** 29.7 2.7
Intaets + SK&F 22340
12.5 mg/kg/day p.o. 59.8 6.5* 56.9 43* 29.4 2.7
25 mg/kg/dayp.o. 49.1 37** 51.2 4.6** 33.7 4.7
50 mg/kg/day p.o. 37.2 3.0** 51.1 45** 28.2 1.4*
100 mg/kg/day p.o. 31.8 2.7*** 52.3 4•3** 27.6 2.6*
a Minimum of six rats per group.
* < .os )
** P < .01 Treatment group vs. intact controls.
P < .001)
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TABLE II
Antiandrogenic activity of SK&F 22340 & 17a-methyl-B-nortestosterone in testosterone-treated castrated rats
Treatment'
Relative organ weights (mg/lOS Gm) (Mean SE.)
Seminal vesicles Ventral prostate Levator ani
Castrate controls 18.3 0.9 12.0 0.9 23.7 1.4
Castrate + testosterone, 2.5mg/kg/day 96.8 7.9 73.1 7.1 42.6 2.4
s.c.
+ l7a -methyl-B -nortestosterone
2Omg/kg/dayp.o. 71.4 6.0* 70.4± 5.1 37.7 2.7
40 mg/kg/day p.o. 66.6 2.4** 61.6 2.3 37.8 1.6
80 mg/kg/day p.o. 51.5 2.6*** 58.3 2.9 31.9 2.9*
160 mg/kg/day p.o. 42.2 2.3*** 41.5 3.6*** 33.1 1.5**
+ SK&F 22340
12.5 mg/kg/day p.o. 68.5 53* 55.0 5.4 37.4 2.4
25 mg/kg/day p.o. 56.2 4.l*** 52.3 7.0 32.8 2.8*
50 mg/kg/day p.o. 44.2 2.8*** 50.0 4.0* 33.0 1.6**
100 mg/kg/day p.o. 33.5 1.9*** 35.6 1.8*** 34.9 1.4*
Minimum of seven rats per group.
* P < .05 1
** P < .01 Treatment group vs. castrate + testosterone group.
P < .001)
exogenous testosterone (2.5 mg/kg/day), SK&F
22340 significantly suppressed the seminal
vesicle weights at all doses tested (Table II).
The ventral prostate weights were signifi-
cantly suppressed at oral doses of 50 and 100
mg/kg, and the levator ani muscle weights
at doses of 25, 50, and 100 mg/kg. As in the
intact rat, the seminal vesicle weight was the
only endpoint which exhibited a dose-response
relationship, and the parallel regression lines
indicated that SK&F 22340 possessed 2.6 times
the antiandrogenic activity of SK&F 7690.
The ability of SK&F 22340 to suppress
chick-comb growth and its comparison with
SK&F 7690 are shown in Figure 1. Total doses
of .025, .05, 0.1, and 0.2 mg of SK&F 22340
100
90•
TESTOS. CONTROLS80
70 x$IE24O
40 NON-Rx CONTROLS
3o.
TOTAL DOSE, MG/CHICK, TOPICAL (LOG SCALE)
Fic. 1. Inhibition of chick-comb growth by SK&F 22340 and SK&F 7690
.025 .05 .1 .2 .4 .8
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were applied topically to the comb over a
seven-day period. They significantly (P <
.01 to < .001) suppressed the comb growth
stimulated by subcutaneously-administered tes-
tosterone oenanthate (0.5 mg/chick). On the
basis of this assay, SK&F 22340 possessed
only 1.5 times the antiandrogenic activity of
SK&F 7690. This was not a statistically sig-
nificant difference in potency.
When SK&F 22340 was administered orally
to castrated immature rats at doses np to
96 mg/kg/day, there was no indication of
androgenic activity when compared to cas-
trated controls. There was a slight but statis-
tically significant (P < .01) increase in levator
ani muscle weight at a dose of 96 mg/kg.
SK&F 22340 possessed weak but definite
uterotrophic activity (Fig. 2). Significant (P <
.001) stimulation of the uterus was apparent
at an oral dose of 12.5 mg/kg/day. SK&F
22340 possessed 8.9 x 10 the uterotrophic
activity of orally-administered ethynyl estra-
diol.
To appraise the significance of the utero-
trophic activity, SK&F 22340 was tested for its
ability to cause vaginal cornifleation in the
mature ovariectomized rat. Seventy-two hours
after the first orally-administered dose of SK&F
22340, 4/15 rats exhibited a eornifled vaginal
epithelium. Under the same experimental eon-
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ditions, SK&F 7690 failed to induce a eorni-
fled vaginal epithelium in any of 15 rats.
In the unilaterally ovariectomized rat,
SK&F 22340 did not inhibit compensatory
ovarian hypertrophy at an oral dose of 100
mg/kg/day. It was also unable to block tes-
tosterone's ability to inhibit ovarian compen-
satory hypertrophy at an SK&F 22340-to-
testosterone ratio of 100: 1.
The effect on sebum production and mitotic
activity of the sebaeeous gland is shown in
Table III. It is clear that estradiol, as expected,
very significantly reduced the sehum production
as measured by the increase of hair fat. 17a-
methyl-B-nortestosterone and SK&F 22340
caused similar marked reductions in sebum pro-
duction at a dose of 10 mg/day and slight,
though not statistically significant, effects at a
dose of one mg/day.
Estradiol did not reduce the incidence of
mitoses. On the other hand, 17a-methyl-B-
nortestosterone and SK&F 22340 suppressed
mitosis to a degree roughly in proportion to
the degree of sebum production. In the last
column of Table III, the mean daily increase
in hair fat has been divided by the means in-
cidence of mitoses for each group of rats. The
quotient, which provides an indication of the
respective synthetic potentials of the sebaeeous
cells, is not decreased either by 17a-methyl-E-
60
SK&F 22340
20 -
OVX. CONTROLS
I I IA I
1.25 2.5 5.0 10 '12.5 25 50 100
DOSE, MCG/KG RO. DOSE, MG/KG P.O.
(LOG SCALE) (LOG SCALE)
Fcc. 2. Uterotrophie activity of SK&F 22340
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TABLE III
Effects of ,S'K&F 2Q40, l7ce-methyl-B-nortestosterone, and estradiol on sebum production and on mitotic
activity in the sebaceous glands of spayed female rats treated wit/i testosterone
Treatment5 Sebum production (increasein hair fat) (mg/Gm hair/
day) (Mean SE.)
Mitosis in sebaceous glands
(per 25 mm section)(Mean SE.)
Scbum/mitosis(X 10')
Testosterone implanted controls
Tastosterone + estradiol
Testosterone + l7cs-methyl-B-nortes-
tosterone (1 mg/day)
Testosterone + 17a-methyl-B-nortes-
tosterone (10 mg/day)
Testosterone + SK&F 22340 (1mg/day)
Testosterone +SK&F 22340 (10mg/day)
0.72 0.094
0.14 0.085***
0.60 0.104 NS
0.24 0062***
0.50 0.073 NS
0.24 0.057***
38.1 10.5
48.5 8.1 NS
40.0 6.9 NS
16.7 6.0 NS
34.5 8.3 NS
11.4 3.0*
19
3
15
14
15
21
Eleven rats per group.P<.os 1
P < .001 Treatment group vs. testosterone implanted controls.
NS = Not significanti
nortestosterone or by SK&F 22340 but is
severely lowered in the estradiol-treated group.
This result suggests that SK&F 22340 inhibits
sebum secretion, in testosterone-treated rats,
entirely by its antiandrogenicity, without any
detectable estrogen-like component in its mode
of action.
DISCUSsION
A 6-cyclopropyl substituent increased the
antiandrogenic activity of 17a-methyl-]-nor-
testosterone in the rat and chick. Since the
6-cyclopropyl analog inhibited exogenous an-
drogen, it appears that the antiandrogenie ef-
fect depends on its ability to effectively com-
pete for reactive sites at the target organ.
This has also been proposed as the mechanism
of action of 17a-methyl-B-nortestosterone (1).
As with 17a-methyl-B-nortestosterone (13),
the ability of SK&F 22340 to suppress pitui-
tary gonadotrophins, as determined by the in-
hibition of compensatory ovarian hypertrophy,
was not manifested at doses well in excess of
those necessary for an antiandrogenic effect.
SK&F 22340 was not capable of inhibiting
the antigonadotrophic effect of testosterone at
dose ratios well in excess of those necessary to
suppress secondary sex organ stimulation.
This may indicate that testosterone possesses
different binding sites or different affinities for
the sites necessary to manifest androgenic and
antigonadotrophic activity.
In view of its antiandrogenic and "estrogen"
activity, it was postulated that SK&F 22340
could have a dual effect on inhibiting sebum
production. The antiandrogenic component
would suppress the sebaceons gland cell pro-
liferation resulting from androgen stimulation.
Simultaneously, the "estrogenic" component
would reduce synthesis within the sebaceous
cells; this latter activity would be independent
of any direct antagonism of androgenic stimu-
lation (12).
The experimental results do not support this
theory. SK&F 22340 suppressed testosterone-
stimulated mitotic activity, clearly demonstrat-
ing antiandrogenic activity. However, its in-
ability to depress the sebum/mitosis quotient
indicates that an estrogenic component did
not contribute to the decrease in sebum pro-
duction.
Rather large doses of estradiol are neces-
sary to suppress sebum production. It is pos-
sible that the extremely weak "estrogenic" ac-
tivity of SK&F 22340 could not be manifested
at the dose employed. It is also possible that
the so-called "estrogenie" activity is not evi-
dence of true estrogenicity. Androgens and
progestins increase uterine weight but do not
increase uterine fluid, as did SK&F 22340. The
induction of a eornified vaginal epithelium is a
specific estrogenic test. The positive results
obtained with SK&F 22340 reflected its weak
estrogenic activity; only 4/15 rats exhibited
eornified vaginal epithelial cells.
SK&F 22340 was more potent than 17ev-
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methyl-B-nortestosterone in suppressing sec-
ondary sex organ weights (seminal vesicles),
but this wan evident in only a slightly, and not
significantly, greater suppression of sebum
production and mitotic activity.
SUMMARY
The incorporation of a 6-cyclopropyl sub-
stituent increased the antiandrogcnic activity of
17a-methyl-B-nortcstosteronc, and appeared to
incorporate slight estrogenic activity. The in-
creased antiandrogenic activity and estrogenic
activity were not reflected in a significantly
greater inhibition of sebum production.
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